Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Cited by (1,051)

Items 701–800 of 1,051

1. Emerging role of PTEN loss in evasion of the immune response to tumours
   Thiago Vidotto, Camila Morais Melo, Erick C. Castelli, Madhuri Koti, Rodolfo Borges dos Reis, Jeremy Andrew Squire · 2020 · British Journal of Cancer
2. The Unfolded Protein Response in Immunogenic Cell Death and Cancer Immunotherapy
   Nicole Rufo, Abhishek Dinkarnath Garg, Patrizia Agostinis · 2017 · Trends in cancer
3. Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy
   Di Pilato, Mauro, Kim, Edward Y., Cadilha, Bruno L., Prüßmann, Jasper N., Nasrallah, Mazen N., Seruggia, Davide, Usmani, Shariq M., Misale, Sandra, Zappulli, Valentina, Carrizosa, Esteban et al. · 2019 · Nature
4. Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
   Tavi Nathanson, Arun Ahuja, Alex Rubinsteyn, Bülent Arman Aksoy, Matthew David Hellmann, Diana Miao, Eliezer M. Van Allen, Taha Merghoub, Jedd D. Wolchok, Alexandra Snyder et al. · 2016 · Cancer Immunology Research
5. Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images
   Wei Mu, Lei Jiang, Yu Shi, Ilke Tunali, Jhanelle E. Gray, Evangelia Katsoulakis, Jie Tian, Robert J. Gillies, Matthew B. Schabath · 2021 · Journal for ImmunoTherapy of Cancer
6. Cancer immunotherapy: it’s time to better predict patients’ response
   Charlotte Pilard, Marie Ancion, Philippe Delvenne, Guy Jérusalem, Pascale Hubert, Michael F. Herfs · 2021 · British Journal of Cancer
7. Neoantigen quality predicts immunoediting in survivors of pancreatic cancer
   Marta Łuksza, Zachary M. Sethna, Luis Alfonso Rojas, Jayon Lihm, Barbara Bravi, Yuval Elhanati, Kevin C. Soares, Masataka Amisaki, Anton Dobrin, David Hoyos et al. · 2022 · Nature
8. Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients
   Xu‐Chao Zhang, Jun Wang, Guoguang Shao, Qun Wang, Xiaotao Qu, Bo Wang, Christopher H. Moy, Yue Fan, Zayed Albertyn, Xiayu Huang et al. · 2019 · Nature Communications
9. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)
   Daniel Carvajal‐Hausdorf, Mehmet Altan, Vamsidhar Velcheti, Scott N. Gettinger, Roy S. Herbst, David L. Rimm, Kurt Alex Schalper · 2019 · Journal for ImmunoTherapy of Cancer
10. The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact
    Lisanne F. van Dessel, Job van Riet, Minke Smits, Yanyun Zhu, Paul Hamberg, Michiel S. van der Heijden, Andries Marinus Bergman, Inge M. van Oort, Ronald de Wit, Emile E. Voest et al. · 2019 · Nature Communications
11. Shared Immunogenic Poly-Epitope Frameshift Mutations in Microsatellite Unstable Tumors
    Vladimir Roudko, Cansu Cimen Bozkus, Theofano Orfanelli, Christopher B. McClain, Caitlin E. Carr, Timothy J. O’Donnell, Lauren Chakraborty, Robert M. Samstein, Kuan‐lin Huang, Stephanie V. Blank et al. · 2020 · Cell
12. Immunotherapy for Breast Cancer: What Are We Missing?
    Vonderheide, Robert H., Domchek, Susan M., Clark, Amy S. · 2017 · Clinical Cancer Research
13. An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors
    Takahiro Ishiguro, Yuji Sano, Shun-ichiro Komatsu, Mika Kamata‐Sakurai, Akihisa Kaneko, Yasuko Kinoshita, Hirotake Shiraiwa, Yumiko Azuma, Toshiaki Tsunenari, Yoko Kayukawa et al. · 2017 · Science Translational Medicine
14. Future cancer research priorities in the USA: a Lancet Oncology Commission
    Elizabeth M. Jaffee, Chi Van Dang, David B. Agus, Brian Michael Alexander, Kenneth Carl Anderson, Alan Ashworth, Anna D. Barker, Roshan Bastani, Sangeeta N. Bhatia, Jeffrey A. Bluestone et al. · 2017 · The Lancet Oncology
15. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
    Anshuman Panda, Janice M. Mehnert, Kim Marie Hirshfield, Gregory Riedlinger, Sherri Damare, Tracie Saunders, Michael Kane, Levi O. Sokol, Mark N. Stein, Elizabeth A. Poplin et al. · 2017 · JNCI Journal of the National Cancer Institute
16. A gene expression signature of TREM2hi macrophages and γδ T cells predicts immunotherapy response
    Donghai Xiong, Yian Wang, Ming You · 2020 · Nature Communications
17. A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers
    Hanada, Ken-ichi, Zhao, Chihao, Gil-Hoyos, Raul, Gartner, Jared J., Chow-Parmer, Christopher, Lowery, Frank J., Krishna, Sri, Prickett, Todd D., Kivitz, Scott, Parkhurst, Maria R. et al. · 2022 · Cancer Cell
18. Claudin-low bladder tumors are immune infiltrated and actively immune suppressed
    Jordan Kardos, Shengjie Chai, Lisle E. Mose, Sara R. Selitsky, Bhavani Krishnan, Ryoichi Saito, Michael D. Iglesia, Matthew I. Milowsky, Joel S. Parker, William Y. Kim et al. · 2016 · JCI Insight
19. PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
    Claud M. Grigg, Naiyer A. Rizvi · 2016 · Journal for ImmunoTherapy of Cancer
20. The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors
    Kyung Hwan Kim, Jinhyun Cho, Bo Mi Ku, Jiae Koh, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Jaekyung Cheon, Young Joo Min, Su‐Hyung Park et al. · 2019 · Clinical Cancer Research
21. Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer
    Wenfeng Fang, Yuxiang Ma, Jiani C. Yin, Shaodong Hong, Huaqiang Zhou, Ao Wang, Fufeng Wang, Hua Bao, Xue Wu, Yunpeng Yang et al. · 2019 · Clinical Cancer Research
22. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma
    Hao Sun, Si‐Yang Maggie Liu, Jiaying Zhou, Jintian Xu, Huang-Kai Zhang, Hong‐Hong Yan, Jiaojiao Huan, Pingping Dai, Chong‐Rui Xu, Jian Su et al. · 2020 · EBioMedicine
23. The Length Distribution of Class I–Restricted T Cell Epitopes Is Determined by Both Peptide Supply and MHC Allele–Specific Binding Preference
    Thomas Trolle, Curtis McMurtrey, John Sidney, Wilfried Bardet, Sean Osborn, Thomas Kaever, Alessandro Sette, William H. Hildebrand, Morten Nielsen, Bjoern Peters · 2016 · The Journal of Immunology
24. Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments
    Jong W. Yu, Sabyasachi Bhattacharya, Niranjan Yanamandra, David Kilian, Hong Shi, Sapna Yadavilli, Yuliya V. Katlinskaya, Heather Kaczynski, Michael Conner, William Benson et al. · 2018 · PLoS ONE
25. B cells and cancer: To B or not to B?
    Wolf H. Fridman, Florent Petitprez, Maxime Meylan, Tom Wei‐Wu Chen, Cheng‐Ming Sun, Lubka T. Roumenina, Catherine Sautès‐Fridman · 2020 · The Journal of Experimental Medicine
26. Applications of Immunogenomics to Cancer
    X. Shirley Liu, Elaine R. Mardis · 2017 · Cell
27. RETRACTED: Nanoscale Metal-Organic Framework Mediates Radical Therapy to Enhance Cancer Immunotherapy
    Kaiyuan Ni, Theint Aung, Shuyi Li, Nina Fatuzzo, Xing‐Jie Liang, Wenbin Lin · 2019 · Chem · Retracted
28. EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
    Xuan Zhu, Lijie Chen, Ling Liu, Xing Niu · 2019 · Frontiers in Oncology
29. Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead
    Kedar Kirtane, Hany Elmariah, Christine H. Chung, Daniel Abate‐Daga · 2021 · Journal for ImmunoTherapy of Cancer
30. Treatment of Advanced Prostate Cancer—A Review of Current Therapies and Future Promise
    Semini Sumanasuriya, Johann Sebastian De Bono · 2017 · Cold Spring Harbor Perspectives in Medicine
31. MuPeXI: prediction of neo-epitopes from tumor sequencing data
    Anne-Mette Bjerregaard, Morten Nielsen, Sine Reker Hadrup, Zoltán Szállási, Aron Charles Eklund · 2017 · Cancer Immunology Immunotherapy
32. Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer
    Jingying Nong, Yuhua Gong, Yanfang Guan, Xin Yi, Yuting Yi, Lianpeng Chang, Ling Yang, Jialin Lv, Zhirong Guo, Hongyan Jia et al. · 2018 · Nature Communications
33. The evolving landscape of biomarker testing for non-small cell lung cancer in Europe
    Keith M. Kerr, Frédéric Bibeau, Erik Thunnissen, Johan Botling, Aleš Ryška, Jürgen Wolf, Katarina Öhrling, Peter Burdon, Umberto Malapelle, Reinhard Büttner · 2021 · Lung Cancer
34. Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer
    Kurt Alex Schalper, Daniel Carvajal‐Hausdorf, Joseph Francis McLaughlin, Mehmet Altan, Vamsidhar Velcheti, Patricia Gaule, Miguel F. Sanmamed, Lieping Chen, Roy S. Herbst, David L. Rimm · 2016 · Clinical Cancer Research
35. Lung cancer in never smokers—the East Asian experience
    Fei Zhou, Caicun Zhou · 2018 · Translational Lung Cancer Research
36. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors
    Nathan O. Siemers, James L. Holloway, Chang Han, Scott D. Chasalow, Petra Ross‐Macdonald, Charles F. Voliva, Joseph D. Szustakowski · 2017 · PLoS ONE
37. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial
    Sandra P. D’Angelo, Shailender Bhatia, Andrew Scott Brohl, Omid Hamid, Janice M. Mehnert, Patrick Andres Maximilian Terheyden, Kent C. Shih, Isaac Brownell, Célèste Lebbé, Karl D. Lewis et al. · 2020 · Journal for ImmunoTherapy of Cancer
38. The Changing Landscape of Therapeutic Cancer Vaccines—Novel Platforms and Neoantigen Identification
    Jessica Jou, Kevin Joseph Harrington, Mai-Britt Zocca, E. Ehrnrooth, Ezra E.W. Cohen · 2020 · Clinical Cancer Research
39. Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
    Remy Thomas, Ghaneya Al‐Khadairi, Julie V. Decock · 2021 · Frontiers in Oncology
40. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation
    Giuseppe Valentino Masucci, Alessandra Cesano, Rachael Elizabeth Hawtin, Sylvia Janetzki, Jenny Zhang, Ilan Richard Kirsch, Kevin K. Dobbin, John David Alvarez, Paul B. Robbins, Senthamil R. Selvan et al. · 2016 · Journal for ImmunoTherapy of Cancer
41. Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy
    Yulian Khagi, Aaron Michael Goodman, Gregory A. Daniels, Sandip Pravin Patel, Assuntina Gesualda Sacco, James Michael Randall, Lyudmila A. Bazhenova, Razelle Kurzrock · 2017 · Clinical Cancer Research
42. The Peptide Vaccine of the Future
    Annika Nelde, Hans‐Georg Rammensee, Juliane S. Walz · 2020 · Molecular & Cellular Proteomics
43. Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes
    Li Zhang, Kenzie D. MacIsaac, Ting Zhou, Pei‐Yu Huang, Chunlin Xin, Jason R. Dobson, Kun Yu, Derek Y. Chiang, Yue Fan, Marc R. Pelletier et al. · 2017 · Molecular Cancer Research
44. Immune microenvironment composition in non‐small cell lung cancer and its association with survival
    Menno Tamminga, T. Jeroen N. Hiltermann, Ed M. D. Schuuring, Wim Timens, Rudolf S.N. Fehrmann, Harry J.M. Groen · 2020 · Clinical & Translational Immunology
45. Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade
    Sneha Berry, Nicolás A. Giraldo, Benjamin Green, Tricia R. Cottrell, Julie E. Stein, Elizabeth L. Engle, Haiying Xu, Aleksandra Ogurtsova, Charles A. Roberts, Daphne Wang et al. · 2021 · Science
46. Whole-exome sequencing and immune profiling of early-stage lung adenocarcinoma with fully annotated clinical follow-up
    Humam N. Kadara, Murim Choi, Jizhong Zhang, Edwin Roger Parra, Jaime Rodriguez‐Canales, Stephen G. Gaffney, Z. Zhao, Carmen Behrens, Junya Fujimoto, Chi-Wan B. Chow et al. · 2016 · Annals of Oncology
47. T-cell Localization, Activation, and Clonal Expansion in Human Pancreatic Ductal Adenocarcinoma
    Ingunn M. Stromnes, Ayaka Hulbert, Robert Hamilton Pierce, Philip D. Greenberg, Sunil R. Hingorani · 2017 · Cancer Immunology Research
48. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
    Paul M Hofman, Simon Heeke, Catherine Alix‐Panabières, Klaus Pantel · 2019 · Annals of Oncology
49. An innate-like Vδ1 + γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer
    Yin Wu, Fernanda Kyle‐Cezar, Richard Woolf, Cristina Naceur‐Lombardelli, Julie Owen, Dhruva Biswas, Anna Lorenc, Pierre Vantourout, Patrycja Gazińska, Anita E. Grigoriadis et al. · 2019 · Science Translational Medicine
50. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
    Xiao Han, Yao Wang, Jianshu Wei, Weidong Han · 2019 · Journal of Hematology & Oncology
51. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer
    Valsamo Anagnostou, Noushin Niknafs, Kristen Ashley Marrone, Daniel C. Bruhm, James Robert White, Jarushka Naidoo, Karlijn Hummelink, Kim Monkhorst, Ferry Lalezari, Mara R. Lanis et al. · 2020 · Nature Cancer
52. Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy
    Leilei Ai, Jian Chen, Hao Yan, Qiaojun He, Peihua Luo, Zhifei Xu, Xiaochun Yang · 2020 · Drug Design Development and Therapy
53. Development of a nanoparticle-based immunotherapy targeting PD-L1 and PLK1 for lung cancer treatment
    Moataz M. Reda, Worapol Ngamcherdtrakul, Molly A. Nelson, Natnaree Siriwon, Ruijie Wang, Husam Y. Zaidan, Daniel S. Bejan, Sherif Reda, Ngoc Ha Hoang, Noah A. Crumrine et al. · 2022 · Nature Communications
54. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors
    Middlebrooks, Candace D, Banday, A Rouf, Matsuda, Konichi, Udquim, Krizia-Ivana, Onabajo, Olusegun O, Paquin, Ashley, Figueroa, Jonine D, Zhu, Bin, Koutros, Stella, Kubo, Michiaki et al. · 2016 · Nature Genetics
55. T cell exhaustion: from pathophysiological basics to tumor immunotherapy
    Kemal Catakovic, Eckhard Klieser, Daniel Neureiter, Roland Geisberger · 2017 · Cell Communication and Signaling
56. Immunoregulatory functions of VISTA
    Elizabeth C. Nowak, Janet Louise Lines, Frederick S. Varn, Jie Deng, Aurélien Sarde, Rodwell Mabaera, Anna Kuta, Isabelle Le Mercier, Chao Cheng, Randolph J. Noelle · 2017 · Immunological Reviews
57. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies
    Hongshu Sui, Ningxia Ma, Ying Wang, Hui Li, Xiaoming Liu, Yanping Su, Jiali Yang · 2018 · Journal of Immunology Research
58. Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade
    Esra A. Akbay, Shohei Koyama, Yan Liu, Ruben Dries, Lauren E. Bufe, Michael Silkes, Md Maksudul Alam, Dillon M. Magee, Robert E. Jones, Masahisa Jinushi et al. · 2017 · Journal of Thoracic Oncology
59. Immunomodulators targeting the PD‐1/PD‐L1 protein‐protein interaction: From antibodies to small molecules
    Jeffrey Yang, Longqin Hu · 2018 · Medicinal Research Reviews
60. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials
    Jackson G. Egen, Wenjun Ouyang, Lawren C. Wu · 2020 · Immunity
61. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
    Elísabeth Pérez-Ruiz, Ignacio Melero, Joanna Kopecka, Ana Bela Sarmento‐Ribeiro, Marilina García‐Aranda, Javier De Las Rivas · 2020 · Drug Resistance Updates
62. FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity
    Theresa L. Whiteside · 2018 · Expert Opinion on Therapeutic Targets
63. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option
    Maartje W. Rohaan, Joost H. van den Berg, Pia Kvistborg, John B.A.G. Haanen · 2018 · Journal for ImmunoTherapy of Cancer
64. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis
    Tyler Joseph Alban, Alvaro G. Alvarado, Mia Dahl Sørensen, Defne Bayık, Josephine Volovetz, Emily Serbinowski, Erin E. Mulkearns-Hubert, Maksim Sinyuk, James S. Hale, Giovana R. Onzi et al. · 2018 · JCI Insight
65. Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors
    Sanjeevani Arora, Rodion A. Velichinskii, Randy W. Lesh, Usman Ali, Michal Jakub Kubiak, Pranshu Bansal, Hossein Borghaei, Martin Joseph Edelman, Yanis Boumber · 2019 · Advances in Therapy
66. Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy
    Luc Cabel, Charlotte Proudhon, Emanuela Romano, Nicolas Girard, Olivier J Lantz, Marc‐Henri Stern, Jean‐Yves Pierga, François‐Clément Bidard · 2018 · Nature Reviews Clinical Oncology
67. Spatial and Temporal Heterogeneity of PD-L1 Expression and Tumor Mutational Burden in Gastroesophageal Adenocarcinoma at Baseline Diagnosis and after Chemotherapy
    Katherine Ismei Zhou, Bryan F. Peterson, Anthony V. Serritella, Joseph Thomas, Natalie Marie Reizine, Stephanie M. Moya, Carol Tan, Yan Wang, Daniel V.T. Catenacci · 2020 · Clinical Cancer Research
68. Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
    Zhengyi Wang, Xiaoying Wu · 2020 · Cancer Medicine
69. Immune Resistance in Lung Adenocarcinoma
    Μάγδα Σπέλλα, Georgios T. Stathopoulos · 2021 · Cancers
70. Resistance mechanisms to immune checkpoint inhibitors: updated insights
    Besan H. Al-Saafeen, Bassam R. Ali, Eyad Elkord · 2025 · Molecular Cancer
71. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma
    Grant L. Lin, Surya Nagaraja, Mariella G. Filbin, Mario L. Suvà, Hannes S. Vogel, Michelle Monje · 2018 · Acta Neuropathologica Communications
72. The therapeutic significance of mutational signatures from DNA repair deficiency in cancer
    Jennifer Ma, Jeremy S. Setton, Nancy Y. Lee, Nadeem Riaz, Simon N. Powell · 2018 · Nature Communications
73. The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment
    Hendry, Shona A., Farnsworth, Rae H., Solomon, Benjamin, Achen, Marc G., Stacker, Steven A., Fox, Stephen B. · 2016 · Frontiers in Immunology
74. The Human Vaccines Project: A roadmap for cancer vaccine development
    Pedro J. Romero, Jacques Banchereau, Nina Bhardwaj, Mark I. Cockett, Mary Lenora Disis, Glenn Dranoff, Eli Gilboa, Scott A. Hammond, Robert D. Hershberg, Alan J. Korman et al. · 2016 · Science Translational Medicine
75. High-Resolution PET Imaging with Therapeutic Antibody-based PD-1/PD-L1 Checkpoint Tracers
    Michael Hettich, Friederike Braun, Mark Daniel Bartholomä, Reinhold Schirmbeck, Gabriele Niedermann · 2016 · Theranostics
76. Mutational landscape of <i>EGFR-</i> , <i>MYC-</i> , and <i>Kras-</i> driven genetically engineered mouse models of lung adenocarcinoma
    McFadden, David G., Politi, Katerina, Bhutkar, Arjun, Chen, Frances K., Song, Xiaoling, Pirun, Mono, Santiago, Philip M., Kim-Kiselak, Caroline, Platt, James T., Lee, Emily et al. · 2016 · Proceedings of the National Academy of Sciences
77. Future prospects of immune checkpoint blockade in cancer: from response prediction to overcoming resistance
    Young‐Jun Park, Da‐Sol Kuen, Yeonseok Chung · 2018 · Experimental & Molecular Medicine
78. Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models
    Vassilis Genoud, Eliana Marinari, Sergey I. Nikolaev, John C. Castle, Valesca Bukur, Pierre‐Yves Dietrich, Hideho Okada, Paul R. Walker · 2018 · OncoImmunology
79. Radiomics of 18F-FDG PET/CT images predicts clinical benefit of advanced NSCLC patients to checkpoint blockade immunotherapy
    Wei Mu, Ilke Tunali, Jhanelle E. Gray, Jin Qi, Matthew B. Schabath, Robert J. Gillies · 2019 · European Journal of Nuclear Medicine and Molecular Imaging
80. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis
    Ying‐Nai Wang, Heng‐Huan Lee, Jennifer L. Hsu, Dihua Yu, Mien‐Chie Hung · 2020 · Journal of Biomedical Science
81. Predictive biomarkers of response for immune checkpoint inhibitors in non–small-cell lung cancer
    Arsela Prelaj, Rebecca Yin Tay, Roberto Ferrara, Nathalie Chaput, Benjamin Besse, Raffaele Califano · 2018 · European Journal of Cancer
82. Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis
    Leitao Sun, Leyin Zhang, Jieru Yu, Yinan Zhang, Xi Pang, Chenghao Ma, Minhe Shen, Shanming Ruan, Harpreet Singh Wasan, Shengliang Qiu · 2020 · Scientific Reports
83. Molecular approaches for classifying endometrial carcinoma
    Josep Maria Piulats, Esther Guerra, Marta Gil-Martín, Berta Roman‐Canal, Sónia Gatius, Rebeca Sanz Pamplona, Ana Velasco, August Vidal, Xavier Matías‐Guiu · 2016 · Gynecologic Oncology
84. Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy
    Jing Li, Weichao Wang, Yajia Zhang, Marcin P. Cieslik, Jipeng Guo, Mengyao Tan, Michael D. Green, Weimin Wang, Heng Lin, Wei Li et al. · 2020 · Journal of Clinical Investigation
85. Current state of immunotherapy for non-small cell lung cancer
    Jyoti Dhar Malhotra, Salma K. Jabbour, Joseph Aisner · 2007 · Translational Lung Cancer Research
86. The Role of the Estrogen Pathway in the Tumor Microenvironment
    Natalie J. Rothenberger, Ashwin Somasundaram, Laura P. Stabile · 2018 · International Journal of Molecular Sciences
87. A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers
    Scott N. Gettinger, Jungmin Choi, Nikita Lavanya Mani, Miguel F. Sanmamed, Ila J. Datar, Ryan Sowell, Victor Y. Du, Edward J. Kaftan, Sarah B. Goldberg, Weilai Dong et al. · 2018 · Nature Communications
88. Correlate tumor mutation burden with immune signatures in human cancers
    Xiaosheng Wang, Mengyuan Li · 2019 · BMC Immunology
89. Detection of Solid Tumor Molecular Residual Disease (MRD) Using Circulating Tumor DNA (ctDNA)
    Chin, Re-I, Chen, Kevin, Usmani, Abul, Chua, Chanelle, Harris, Peter K., Binkley, Michael S., Azad, Tej D., Dudley, Jonathan C., Chaudhuri, Aadel A. · 2019 · Molecular Diagnosis &amp; Therapy
90. Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
    Cristina Puig-Saus, Barbara Sennino, Songming Peng, Clifford L. Wang, Zheng Pan, Benjamin Yuen, Bhamini Purandare, Duo An, Boi Bryant Quach, Diana Nguyen et al. · 2023 · Nature
91. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
    Arvind Ravi, Matthew David Hellmann, Monica B. Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama et al. · 2023 · Nature Genetics
92. Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation
    Robert Louis Ferris, Heinz‐Josef Lenz, Anna Maria Trotta, Jesús García‐Foncillas, Jeltje Schulten, François Audhuy, Marco Carlo Merlano, Gerard Alain Milano · 2017 · Cancer Treatment Reviews
93. Genomic ERBB2 / ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis
    Maolan Li, Fatao Liu, Fei Zhang, Weiping Zhou, Xiaoqing Jiang, Yuan Yang, Kai Qu, Yueqi Wang, Qiang Ma, Ting Wang et al. · 2018 · Gut
94. Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC
    Julia Kargl, Xiaodong Zhu, Huajia Zhang, Grace H. Y. Yang, Travis J. Friesen, Melissa Shipley, Dean Y. Maeda, John A. Zebala, Jill McKay-Fleisch, Gavin D. Meredith et al. · 2019 · JCI Insight
95. Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
    Bingxi He, Di Dong, Yunlang She, Caicun Zhou, Mengjie Fang, Yongbei Zhu, Henghui Zhang, Zhipei Huang, Tao Jiang, Jie Tian et al. · 2020 · Journal for ImmunoTherapy of Cancer
96. A transformer-based model to predict peptide–HLA class I binding and optimize mutated peptides for vaccine design
    Yanyi Chu, Yan Zhang, Qiankun Wang, Lingfeng Zhang, Xuhong Wang, Yanjing Wang, Dennis Russell Salahub, Qin Xu, Jianmin Wang, Xue Xiang Jiang et al. · 2022 · Nature Machine Intelligence
97. Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape
    Jiawen Cui, Yao Li, Yang Yang, Hai‐Kui Yang, Jia-Mei Dong, Zhi-Hua Xiao, Xin He, Jiahao Guo, Ruiqi L. Wang, Bo Dai et al. · 2024 · Biomedicine & Pharmacotherapy
98. New immunotherapies targeting the PD-1 pathway
    Jordan M. Chinai, Murali Janakiram, Fuxiang Chen, Wantao Chen, Mark Kaplan, Xingxing Zang · 2015 · Trends in Pharmacological Sciences
99. Biomarkers for immunotherapy in bladder cancer: a moving target
    David Henry Aggen, Charles G. Drake · 2017 · Journal for ImmunoTherapy of Cancer
100. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues
     Majzner, Robbie G., Simon, Jason S., Grosso, Joseph F., Martinez, Daniel, Pawel, Bruce R., Santi, Mariarita, Merchant, Melinda S., Geoerger, Birgit, Hezam, Imene, Marty, Virginie et al. · 2017 · Cancer